141 related articles for article (PubMed ID: 38287179)
1. A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Burris HA; Berlin J; Arkenau T; Cote GM; Lolkema MP; Ferrer-Playan J; Kalapur A; Bolleddula J; Locatelli G; Goddemeier T; Gounaris I; de Bono J
Br J Cancer; 2024 Apr; 130(7):1131-1140. PubMed ID: 38287179
[TBL] [Abstract][Full Text] [Related]
2. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
3. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
Lozinski M; Bowden NA; Graves MC; Fay M; Day BW; Stringer BW; Tooney PA
Oncotarget; 2024 Jan; 15():1-18. PubMed ID: 38227740
[TBL] [Abstract][Full Text] [Related]
5. Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators.
Jadav R; Weiland F; Noordermeer SM; Carroll T; Gao Y; Wang J; Zhou H; Lamoliatte F; Toth R; Macartney T; Brown F; Hastie CJ; Alabert C; van Attikum H; Zenke F; Masson JY; Rouse J
Mol Cell Proteomics; 2024 Jun; ():100802. PubMed ID: 38880245
[TBL] [Abstract][Full Text] [Related]
6. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA; Krebs MG; Postel-Vinay S; El-Khouiery A; Soria JC; Lopez J; Berges A; Cheung SYA; Irurzun-Arana I; Goldwin A; Felicetti B; Jones GN; Lau A; Frewer P; Pierce AJ; Clack G; Stephens C; Smith SA; Dean E; Hollingsworth SJ
Clin Cancer Res; 2021 Oct; 27(19):5213-5224. PubMed ID: 34301752
[TBL] [Abstract][Full Text] [Related]
7. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
[TBL] [Abstract][Full Text] [Related]
8. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
9. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
10. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma.
Seidel P; Rubarth A; Zodel K; Peighambari A; Neumann F; Federkiel Y; Huang H; Hoefflin R; Adlesic M; Witt C; Hoffmann DJ; Metzger P; Lindemann RK; Zenke FT; Schell C; Boerries M; von Elverfeldt D; Reichardt W; Follo M; Albers J; Frew IJ
JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36413415
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R; Plummer R; Jones R; Carter L; Blagden S; Sarker D; Arkenau T; Evans TRJ; Danson S; Symeonides SN; Veal GJ; Klencke BJ; Kowalski MM; Banerji U
Br J Cancer; 2023 Jul; 129(1):38-45. PubMed ID: 37120671
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG
Invest New Drugs; 2018 Oct; 36(5):886-894. PubMed ID: 29766337
[TBL] [Abstract][Full Text] [Related]
13. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Wang-Gillam A; Schelman W; Ukrainskyj S; Chien C; Gonzalez M; Yang Z; Kania M; Yeckes-Rodin H
Invest New Drugs; 2023 Dec; 41(6):851-860. PubMed ID: 37796398
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Von Hoff DD; Rasco DW; Heath EI; Munster PN; Schellens JHM; Isambert N; Le Tourneau C; O'Neil B; Mathijssen RHJ; Lopez-Martin JA; Edenfield WJ; Martin M; LoRusso PM; Bray GL; DiMartino J; Nguyen A; Liu K; Laille E; Bendell JC
Clin Cancer Res; 2018 Sep; 24(17):4072-4080. PubMed ID: 29764853
[No Abstract] [Full Text] [Related]
16. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
17. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
[TBL] [Abstract][Full Text] [Related]
19. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
